. Author manuscript; available in PMC: 2009 Nov 1.

Published in final edited form as: Int J Cancer. 2008 Nov 1;123(9):2031–2040. doi: 10.1002/ijc.23732

Table 2.

Effect of drugs on cell proliferation and cytokine production by H460 cells

Ex p#	Groups	No. cells (× 10³)	Cytokines, (pg/1×10⁶cells)
Ex p#	Groups	No. cells (× 10³)	IL-6	IL-8	VEGF	bFGF	G-CSF	CCL2	CCL5
A1	Control	1,000±212	5,118	7,594	596	24	0	0	0
	Doxo	90±23^*	116,955^*	94,484^*	4,108^*	518^*	514^*	139^*	276^*
	Cispl	100±31^*	213,068^*	107,964^*	6,664	742^*	1,104^*	356^*	920^*
A2	Control	47±8	5,970	15,349	638	34	0	11	0
	PostDoxo	9 ±1^*	137,689^*	103,911^*	3,177^*	267^*	623^*	59^*	111^*
	PostCispl	20±3^*	121,120^*	57,590^*	3,530^*	280^*	60^*	178^*	80^*

Experiment A1: H460 tumor cells were seeded into a 24-well plate (2×10⁵/well), with 8 wells per group, and cultured for 3 days in the presence of doxorubicin (0.125μg/ml) or cisplatin (0.3μg/ml). Supernatants were collected and cells were counted. The concentrations of TPFs in the supernatants were analyzed using a multiplex immunobeads kit and data were calculated as pg/1×10⁶ cells.

Experiment A2: Cells collected from the control and drug-treated groups (experiment A1) were seeded into a 96-well plate (1×10⁴ cells/well) in fresh media without any drug. After 3 days, supernatants were collected and the numbers of cells were estimated using the One Solution Cell Proliferation Kit (Promega).

Differences between control and experimental groups were significant (p<0.05).